Oral Sucrose for Heel Lance Increases Adenosine Triphosphate Use and Oxidative Stress in Preterm Neonates

Yayesh Asmerom, MS1, Laurel Slater, BSN, RNC1, Danilo S. Boskovic, PhD1, Khaled Bahjri, MD2, Megan S. Holden, BS1, Raylene Phillips, MD3, Douglas Deming, MD3, Stephen Ashwal, MD3, Elba Fayard, MD3, and Danilyn M. Angeles, PhD1

Objective To examine the effects of sucrose on pain and biochemical markers of adenosine triphosphate (ATP) degradation and oxidative stress in preterm neonates experiencing a clinically required heel lance.

Study design Preterm neonates that met study criteria (n = 131) were randomized into 3 groups: (1) control; (2) heel lance treated with placebo and non-nutritive sucking; and (3) heel lance treated with sucrose and non-nutritive sucking. Plasma markers of ATP degradation (hypoxanthine, xanthine, and uric acid) and oxidative stress (allantoin) were measured before and after the heel lance. Pain was measured with the Premature Infant Pain Profile. Data were analyzed by the use of repeated-measures ANOVA and Spearman rho.

Results We found significant increases in plasma hypoxanthine and uric acid over time in neonates who received sucrose. We also found a significant negative correlation between pain scores and plasma allantoin concentration in a subgroup of neonates who received sucrose.

Conclusion A single dose of oral sucrose, given before heel lance, significantly increased ATP use and oxidative stress in premature neonates. Because neonates are given multiple doses of sucrose per day, randomized trials are needed to examine the effects of repeated sucrose administration on ATP degradation, oxidative stress, and cell injury. (J Pediatr 2013;163:29-35).

Methods

We conducted a prospective double-blind randomized controlled study at Loma Linda University Children’s Hospital neonatal intensive care unit. Study...
protocol and informed consent documents were approved by the Loma Linda University Children’s Hospital Institutional Review Board. Subjects included in the study were premature infants ≤36.5 weeks gestation who: (1) weighed ≥800 g; (2) had a central catheter in place; and (3) required a heel lance. Exclusion criteria included neonates: (1) with unstable oxygenation and hemodynamic status; (2) receiving opioids or sedatives or any antiepileptic medications; (3) diagnosed with intraventricular hemorrhage ≥ grade 3; or (4) with facial or multiple congenital anomalies that might alter the pain response. The heel lance was performed for an accurate measurement of blood glucose from neonates receiving glucose-rich total parenteral nutrition through a central catheter. Parents of premature infants who met study criteria were approached for informed consent as soon after birth as possible. With consent, subjects were randomized into 1 of 3 groups: (1) control; (2) placebo with non-nutritive sucking (NNS, or pacifier); or (3) sucrose (Sweet-Ease; Children’s Medical Ventures, Phillips Healthcare, Andover, Massachusetts) with NNS (Figure 1; available at www.jpeds.com). Randomization was performed by a research pharmacist, who used a permuted block randomization table generated by the study statistician.

The experimental procedure is described in Figure 2 (available at www.jpeds.com). Investigators collaborated with the clinical staff to obtain a sample of approximately 0.8 mL of blood from a central catheter before (“0” minute) and 5 minutes after the heel lance to measure purine and allantoin levels. In control neonates who did not receive a study drug or undergo a heel lance, similar samples were collected at “0” and 5 minutes from baseline. The time period of 5 minutes after heel lance for blood sample collection was based on previous investigations, which showed plasma levels of purines and organic hydroperoxides significantly increasing 5 minutes after conditions such as incomplete ischemia. These data were validated by unpublished preliminary studies in our laboratory, where we found increases in plasma purines compared with baseline five minutes after heel lance, and purine values that were less than baseline, 20-30 minutes after heel lance. Blood samples were centrifuged within 5 minutes to separate the plasma which was then stored at −80°C. All samples were analyzed within 1 week of acquisition.

Heel Lance Procedure and Administration of Study Drug
The study drug was prepared immediately before the experimental procedure by the research pharmacist and labeled as “study drug” to ensure blinding. The dose of sucrose was based on previously published studies in premature infants. Neonates randomized to the sucrose group received a single dose of 24% sucrose in the following volumes: 2 mL for neonates >2 kg, 1.5 mL for neonates 1.5-2 kg, and 0.5 mL for neonates that were <1.5 kg. The study drug was administered slowly via syringe to the anterior tongue along with a pacifier (NNS) 2 minutes before the heel lance. Multiple studies showed that sucrose was most effective when given approximately two minutes before heel lance.2,18-23 Neonates randomized to the placebo group received an equal volume of sterile water to the anterior portion of the tongue along with a pacifier. The neonate’s face was videotaped by trained research staff to record facial action at “0” minutes, during the heel lance and up to 30 seconds post heel lance.

Pain Assessment
To assess pain, we used the PIPP, an instrument designed to assess acute pain in preterm neonates. This scoring system includes seven items, each graded from 0 to 3. Two items describe baseline characteristics of the neonate (gestational age and behavioral state), 2 items are derived from physiologic measurements (heart rate and oxygen saturation), and 3 items describe facial actions (brow bulge, eye squeeze, and nasolabial furrow). Baseline pain was scored before the heel lance (0 minute) during a 30-second window. Procedural pain was scored from the time of heel lance to 30 seconds after the lance. Facial actions were recorded with a digital camera with real-time counter that allowed for intensive slow motion stop frame, videocoding, and playback. Previous work on validation of the PIPP score showed an ability to differentiate painful from non-painful or baseline events.3,13,24

Measurement of Purines
Purine metabolites were measured as previously published by our laboratory. Specifically, plasma was removed, transferred to separate Eppendorf tubes, and immediately centrifuged in Eppendorf 5702R (Pittsburgh, Pennsylvania) centrifuge, for 30 minutes at 18,000 g. The supernatant was transferred to Microcon centrifugal filter devices (Millipore Corp, Bedford, Massachusetts), 200 μL per device, and spun for 90 minutes at 14,000 g, 4°C. Filtrate was removed, and 150 μL was transferred to an Eppendorf tube containing 1 × 10⁻⁷ mol of 2-aminopurine (internal standard). High-performance liquid chromatography (Waters 996 PDA, 715 Ultra Wisp Sample Processor; Millipore Corp) analysis was done in the same day, or the tubes were frozen at −80°C until analysis. Previous analysis via high-performance liquid chromatography of plasma demonstrated that purines remained stable with freezing.

Three 45-μL injections were used for each sample onto a Supelcosil LC-18-S 15 cm × 4.6 mm, 5-μm column (SGE, Austin, Texas), with the following isocratic conditions: 50 mM ammonium formate buffer, pH 5.5, flow rate 1.0 mL/min. Hypoxanthine, xanthine, and uric acid were quantitated by obtaining peak areas at appropriate retention and wavelengths.20 Once the peak area of 2-aminopurine at approximately 10.8 minutes and 305 nm was determined, the area ratios of hypoxanthine, xanthine, and uric acid to 2-aminopurine were determined and converted to micromolar concentrations using standard curves. Samples were analyzed in triplicates and values with a coefficient of variation of less than 10% were included in the final analyses. The limits of
Measurement of Allantoin. Allantoin was measured in plasma using an adaptation of the method developed by Gruber et al27 and Al-Khalaf and Reaveley.28 Plasma (50 μL) was transferred to an Eppendorf tube containing 5 × 10⁻¹⁰ mol internal standard (50 μL 10 μM [¹⁵N]-labeled allantoin). Spiked samples were simultaneously denitrogenized and extracted by the addition of 100 μL of acetonitrile. These samples were then vortexed and centrifuged at 20 000 g, 4°C for 5 minutes, and the supernatant was dried under N₂. After drying, 50 μL of MTBSTFA (ie, N-methyl-N-tert-butyldimethylsilyltrifluoroacetamide) in pyridine (1:1 vol/vol) was added and the derivatization reaction was facilitated by incubation at 50°C for 2 hours. Analysis was performed on Agilent 6890N Network GC System connected to an Agilent 5973 Inert Mass Selective Detector (both Agilent Technologies, Inc, Santa Clara, California). Separation was performed using an Agilent 122-5532G capillary column (25.7 m length, 0.25 mm internal diameter). Helium was used as the carrier gas at a flow rate of 1.5 mL/min. Derivatized product (1 μL) was injected in split mode (split 20:1, split flow 29.4 mL/min, total flow 33.8 mL/min). The initial column temperature was set at 100°C and held at that temperature for 2 minutes; it was increased to 180°C at a rate of 10°C/min. The column was held at this temperature for 4 minutes and then increased to 260°C at a rate of 20°C/min. This temperature was maintained until the end of the run. Allantoin was quantified using selected ion monitoring mode with the 398.00 m/z ion being monitored for allantoin and the 400.00 m/z for DL-allantoin-5-¹³C₁₁⁻¹⁵N. The ion abundance ratios (398.00/400.00) were converted to micromolar concentrations by use of a standard curve.

Statistical Analyses. A repeated-measures ANOVA with one between factor (type of intervention) and one within factor (time) was used to compute the minimum sample size needed for this study. The sample size was based on the following assumptions: (1) the significance level was set to 0.05; and (2) required power was 80%. After adjusting for a 10% dropout rate, we enrolled 42-45 participants per group for a total of 131 subjects.

To analyze the data, assumptions of normality and equal variance were assessed. Demographic data for categorical variables were analyzed by use of the χ² test. Repeated-measures ANOVA for one between subject factor (group) and one within subject factor (time) were assessed to evaluate the effect of the heel lance on plasma purines and allantoin concentrations over time. Interaction terms in the general linear model were used for this purpose. The interaction terms assess the differences between the groups over time. Correlations between purines, allantoin, and biobehavioral markers (PIPP) were examined with the Spearman rho. All statistical analyses were performed using SPSS Statistics for Windows Version 20 (SPSS Inc, Chicago, Illinois). Differences were considered significant at P < .05.

Results

Of the 151 subjects who provided consent between the months of July 2009 and February 2012, 131 subjects were randomized into 1 of 3 groups: control (n = 42), heel lance and placebo (n = 45), or heel lance and 24% sucrose (n = 44; Figure 1). All subjects randomized to the heel lance groups were given a pacifier (NNS) immediately before, during, and after study drug administration. There were no significant differences between the groups (Table I).

Effects of Oral Sucrose on Behavioral and Physiological Markers of Pain

There were no significant differences in baseline pain score between the 3 groups (Table II). Sucrose significantly attenuated the increase in pain score in response to heel lance, compared with placebo (Table II). The heart rate response to heel lance was greatest in the sucrose group (P < .001). Heart rate increased by 11% in the sucrose group, compared with 6% in the placebo group and 0.5% in the control group. We observed no significant changes in mean oxygen saturation in response to heel lance in any of the 3 groups. These data suggest that the lower pain scores in the sucrose group were attributable to significant reductions in the behavioral components of the PIPP scoring tool and not from physiological markers of pain such as heart rate or oxygen saturation.

Effects of Oral Sucrose on Markers of ATP Metabolism (Purines) and Oxidative Stress (Allantoin)

There were no significant differences in baseline purine and allantoin levels in any of the groups. However, although plasma purine and allantoin concentration decreased over time in subjects randomized to the control and placebo groups, we observed a significant increase over time in plasma hypoxanthine and uric acid in neonates who received sucrose before the heel lance (Figure 3, A and B). This effect persisted even when analysis was limited to subjects <33 weeks’ gestation at the time of sampling. Xanthine concentrations remained stable over time in each of the 3 groups. Plasma allantoin concentration increased over time in those who received sucrose; however, this effect was not statistically significant (data not shown).

Effects of Oral Sucrose on Plasma Allantoin in Neonates with a Minimal Pain Response to Heel Lance

We found that 63% of neonates who received sucrose demonstrated a minimal response to heel lance, defined as an increase in PIPP score of <33%. When we examined the effect of sucrose in this subgroup, we found that plasma allantoin concentration increased significantly over time (Figure 3,
When we examined the correlation between the percent change in PIPP pain score over time and the percent change in allantoin concentration over time, we found a significant negative correlation (Spearman rho, −0.378, P = .014), suggesting that although sucrose significantly decreased the pain scores, it also increased markers of oxidative stress in this subgroup of premature neonates.

**Discussion**

Although oral sucrose given before a single heel lance significantly decreased behavioral markers of pain, consistent with the findings of numerous clinical investigators,8,17,23,29 it also increased markers of ATP use, as evidenced by significant increases over time in plasma hypoxanthine and uric acid concentrations. The relationship between sucrose, ATP use/depletion, and increased purine production is well documented in adult animal and human literature (Figure 4),6,30,31 Sucrose is a disaccharide of glucose and fructose. It is hydrolyzed by sucrase, an enzyme secreted by epithelial cells of the villi in the small intestine (Figure 4, A). Both glucose and fructose are rapidly absorbed from the gastrointestinal tract through glucose transporter (GLUT) 5 (fructose) and sodium-glucose cotransporter/GLUT2 (glucose) transporters in the apical membrane and transferred to the portal circulation via GLUT2 transporters in the basolateral membrane of enterocytes (Figure 4, B).

The expression of these GLUTs is up-regulated by exposure of intestinal lumen to fructose solutions32 or by previous exposure to corticosteroids.33 Once in circulation, glucose uptake is insulin-dependent while fructose uptake is independent of

### Table I. Subject demographics

<table>
<thead>
<tr>
<th></th>
<th>Control (n = 42)</th>
<th>Heel lance, placebo-NNS (n = 45)</th>
<th>Heel lance, Sweet-Ease/NNS (n = 44)</th>
<th>F value</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>EGA, weeks</td>
<td>30.5 ± 2.6</td>
<td>30.3 ± 3.2</td>
<td>30.1 ± 3.1</td>
<td>0.218*</td>
<td>.804</td>
</tr>
<tr>
<td>Birth weight, g</td>
<td>1456.4 ± 502</td>
<td>1498.4 ± 706</td>
<td>1374.1 ± 562</td>
<td>0.499*</td>
<td>.608</td>
</tr>
<tr>
<td>Apgar, 1 minute</td>
<td>5 ± 3</td>
<td>5 ± 3</td>
<td>6 ± 2</td>
<td>0.961*</td>
<td>.385</td>
</tr>
<tr>
<td>Apgar, 5 minute</td>
<td>7 ± 2</td>
<td>7 ± 2</td>
<td>7 ± 2</td>
<td>1.008*</td>
<td>.368</td>
</tr>
<tr>
<td>Sex, n (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>25 (60%)</td>
<td>22 (49%)</td>
<td>22 (50%)</td>
<td>1.175†</td>
<td>.556</td>
</tr>
<tr>
<td>Female</td>
<td>17 (40%)</td>
<td>23 (51%)</td>
<td>22 (50%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Race, n (%)</td>
<td></td>
<td></td>
<td></td>
<td>4.277†</td>
<td>.831</td>
</tr>
<tr>
<td>White</td>
<td>15 (36%)</td>
<td>14 (31%)</td>
<td>19 (43%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hispanic</td>
<td>15 (36%)</td>
<td>21 (47%)</td>
<td>15 (34%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>African American</td>
<td>6 (14%)</td>
<td>7 (16%)</td>
<td>6 (14%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Asian</td>
<td>2 (4%)</td>
<td>2 (4%)</td>
<td>2 (4.5%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td>4 (10%)</td>
<td>1 (2%)</td>
<td>2 (4.5%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Condition at time of sampling</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>F_{O_2}, %</td>
<td>0.25 ± 0.07</td>
<td>0.26 ± 0.09</td>
<td>0.23 ± 0.03</td>
<td>1.783*</td>
<td>.172</td>
</tr>
<tr>
<td>EGA, weeks</td>
<td>32.5 ± 2.3</td>
<td>32.6 ± 2.6</td>
<td>33.1 ± 2.1</td>
<td>0.759*</td>
<td>.470</td>
</tr>
<tr>
<td>SNAPPE-II</td>
<td>7.8 ± 10.8</td>
<td>7.9 ± 11.9</td>
<td>8.3 ± 11.6</td>
<td>0.020*</td>
<td>.980</td>
</tr>
<tr>
<td>Mode of O_{2} delivery</td>
<td></td>
<td></td>
<td></td>
<td>6.861†</td>
<td>.334</td>
</tr>
<tr>
<td>Spontaneous RA</td>
<td>19</td>
<td>19</td>
<td>24</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nasal cannula</td>
<td>6</td>
<td>11</td>
<td>11</td>
<td></td>
<td></td>
</tr>
<tr>
<td>NCPAP</td>
<td>6</td>
<td>6</td>
<td>1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>NIPPV</td>
<td>11</td>
<td>0</td>
<td>8</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hemoglobin</td>
<td>13.1 ± 2.4</td>
<td>12.7 ± 2.3</td>
<td>12.5 ± 2.2</td>
<td>0.846*</td>
<td>.432</td>
</tr>
<tr>
<td>Hematocrit</td>
<td>38.7 ± 6.5</td>
<td>37.6 ± 6.4</td>
<td>36.9 ± 5.7</td>
<td>0.844*</td>
<td>.433</td>
</tr>
</tbody>
</table>

EGA, estimated gestational age; NCPAP, nasal continuous positive airway pressure; NIPPV, noninvasive intermittent positive pressure ventilation; RA, room air; SNAPPE-II, Score for Neonatal Acute Physiology–Perinatal Extension-II.

*Repeated-measure ANOVA.
†x² test.

### Table II. Pain score, heart rate, and oxygen saturation

<table>
<thead>
<tr>
<th></th>
<th>Control (n = 42)</th>
<th>Heel lance, placebo-NNS (n = 45)</th>
<th>Heel lance, Sweet-Ease/NNS (n = 44)</th>
<th>F value</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pain score</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean (min-max)</td>
<td>3.9 (1-8)</td>
<td>3.8 (1-8)</td>
<td>3.8 (1-7)</td>
<td>0.233*</td>
<td>.792</td>
</tr>
<tr>
<td>Procedural</td>
<td>5.9 (2-15)</td>
<td>6.3 (2-12)</td>
<td>4.6 (2-10)</td>
<td>6.216*</td>
<td>.003†</td>
</tr>
<tr>
<td>Heart rate</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline</td>
<td>154.4 (12.8)</td>
<td>155.9 (14.4)</td>
<td>154.1 (13.3)</td>
<td>0.206*</td>
<td>.814</td>
</tr>
<tr>
<td>Procedural</td>
<td>154.9 (13.9)</td>
<td>164.9 (14.6)</td>
<td>170.5 (14.7)</td>
<td>14.480* &lt;.001‡</td>
<td></td>
</tr>
<tr>
<td>Oxygen saturation</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline</td>
<td>96.5 (0.5)</td>
<td>96.2 (0.5)</td>
<td>96.2 (0.5)</td>
<td>0.123*</td>
<td>.885</td>
</tr>
<tr>
<td>Procedural</td>
<td>96.2 (0.6)</td>
<td>95.8 (0.6)</td>
<td>96.4 (0.6)</td>
<td>0.235*</td>
<td>.791</td>
</tr>
</tbody>
</table>

*Repeated-measures ANOVA.
†Sweet-Ease group significantly lower than control or placebo groups.
‡Control group significantly lower than both heel lance groups.
Inside the cell, fructose is rapidly phosphorylated into fructose-1-phosphate by the enzyme fructokinase (Figure 4, C). The activity of fructokinase is 4-fold greater than glucokinase (the enzyme that phosphorylates glucose). Moreover, fructokinase activity is relatively unregulated, being limited only by fructose concentration. Fructose-1-phosphate is split by aldolase (aldolase B) into glyceraldehyde and dihydroxyacetone phosphate, a member of the glycolysis sequence of intermediates. The third enzyme in the fructose pathway is triokinase, which catalyzes the phosphorylation of glyceraldehyde to glyceraldehyde-3-phosphate, another intermediate in the glycolytic pathway.

These fructose-related biochemical reactions are significant because each phosphorylation step requires ATP. As ATP is consumed, it is degraded to ADP, leading to an increase in ADP concentration. Simultaneously, inorganic phosphate levels decrease because they are sequestered in fructose-1-phosphate or the mitochondria to generate ATP necessary to maintain fructose phosphorylation (Figure 4, D). As inorganic phosphate concentration decreases, oxidative phosphorylation is inhibited, reducing ATP synthesis and rapidly depleting ATP. ATP and ADP catabolism results in increased concentration of purines such as uric acid (Figure 4, E). These observations have been documented in adult animals as well as in children ages 11 months to 12 years and in healthy adults. We show similar effects in preterm neonates, in which a single dose of sucrose significantly increased plasma hypoxanthine and uric acid concentrations.

We also found that neonates in the sucrose treatment group had the largest increase in heart rate compared with those in the control or placebo groups, providing additional evidence that sucrose does not attenuate the tachycardia that accompanies painful procedures, but may increase it. This increase in heart rate may be due to the stimulatory effect of sucrose on the sympathetic nervous system, as shown in rats and healthy young adults. Interestingly, in humans, the sympathetic response to sucrose ingestion was enhanced under conditions of acute moderate hypoxia. Together, these data suggest that the apparent analgesic effect of oral sucrose may come at a price, namely tachycardia, which in turn contributes to increased ATP use.

An additional finding of this study is the effect of sucrose administration on plasma allantoin concentration in neonates with reduced pain responses (PIPP score increased by <33%). We found that in this subgroup, plasma allantoin concentration significantly increased over time, compared with neonates with a larger pain response (defined as having an increase in PIPP score of ≥34% compared with baseline; Figure 3, C). The demographics of this subgroup of neonates were not significantly different from those with a larger pain response. Although newborns with reduced pain responses had significantly lower baseline heart rates (151 ± 11.6 beats/min vs 159 ± 14.4 beats/min, P = .028), they tended to have a greater percent change in heart rate with the heel lance procedure compared with those with larger pain responses (12 ± 7% vs 9 ± 7%, P = .290). These data suggest that changes in heart rate due to sucrose administration may be more predictive of oxidative stress than changes in facial or behavioral activity.
studies are required to examine the relationship between sucrose administration, pain reactivity, and oxidative stress. A limitation of this study is that although statistical power of more than 80% was achieved for hypoxanthine and uric acid, it was not achieved for allantoin. A larger sample size may be required to adequately examine the effect of sucrose treatment on allantoin. It is possible that a significant increase in allantoin may not be always evident five minutes after the heel lance procedure.

In this prospective, randomized, double-blind study, we made the observation that a single dose of oral sucrose, given before a heel lance, significantly increased markers of ATP use and oxidative stress in premature neonates over time. This finding suggests that the apparent analgesic effect of

---

**Figure 4. Sucrose metabolism.**

A Sucrose is hydrolyzed into fructose and glucose by the enzyme sucrase. B, Glucose and fructose are absorbed from the gastrointestinal tract, transferred to the portal circulation, and enter hepatocytes. C, Fructose is phosphorylated to form fructose-1-phosphate by the enzyme fructokinase. D, Fructose phosphorylation rapidly depletes the cell of ATP and inorganic phosphate. E, Decreases in ATP production, in addition to increased ATP utilization, results in increased hypoxanthine, xanthine, and uric acid production. If this is combined with increased oxidative stress, uric acid can be oxidized to form allantoin. *SGLT*, sodium-glucose cotransporter; *ISF*, interstitial fluid; *TCA*, tricarboxylic acid cycle; *IMP*, inosine monophosphate.
oral sucrose may come at a price, namely increased ATP use. Because neonates can be exposed to numerous painful procedures per day requiring multiple doses of sucrose, randomized trials should be performed to examine the effects of repeated sucrose administration not only on markers of ATP breakdown and oxidative stress but also on cellular injury. If it is determined that the metabolic risks of using sucrose in neonates is indeed greater than the known benefits of reducing behavioral indices of pain, additional studies need to be performed to identify alternative effective substances or methods to prevent or treat pain in neonates. ■

We want to thank Desiree Wallace, PharmD and all the nurses and physicians at Loma Linda University Children’s Hospital for their support of this study.

Submitted for publication Aug 22, 2012; last revision received Oct 30, 2012; accepted Dec 27, 2012.

Reprint requests: Danilyn M. Angeles, PhD, Division of Physiology, Department of Basic Sciences, Loma Linda University School of Medicine, Loma Linda, CA 92350. E-mail: dangeles@llu.edu

Oral Sucrose for Heel Lance Increases Adenosine Triphosphate Use and Oxidative Stress in Preterm Neonates

References

Figure 1. Enrollment flow chart. *Reasons why subjects were not sampled include: change in acuity or failure to meet study criteria after consent was obtained (n = 9); central line will not draw or lipids were being infused preventing sampling (n = 5); and line was discontinued before sampling could be scheduled (n = 6).

Figure 2. Study procedure.

*Control neonates received no study drug, no heel lance. PIPP and plasma markers are obtained at baseline and five minutes after baseline.